Home » Otsuka Can Block Generic Abilify as Court Rejects Appeal
Otsuka Can Block Generic Abilify as Court Rejects Appeal
The U.S. Supreme Court left intact a ruling that lets Otsuka Holdings (4578)’s pharmaceutical unit block generic competition to its schizophrenia drug Abilify in the U.S. until April 2015.
Bloomberg
Bloomberg
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May